Trinity Biotech plc (TRIB)
-NasdaqGS | Prev Close: | 16.88 |
|---|
| Open: | N/A |
|---|
| Bid: | 12.22 x 500 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 21.13 |
|---|
| Beta: | 0.56 |
|---|
| Next Earnings Date: | 10-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 10.89 - 19.00 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 77,736 |
|---|
| Market Cap: | 365.13M |
|---|
| P/E (ttm): | 21.98 |
|---|
| EPS (ttm): | 0.77 |
|---|
| Div & Yield: | 0.15 (0.90%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Trinity Biotech PLC CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri, Apr 26)
- Trinity Biotech Announces Quarter 1 Results - EPS of 20 Cents, Premier Regulatory Approval in China and 33% Increase in Dividend to 20 CentsGlobeNewswire(Thu, Apr 25)
- Q1 2013 Trinity Biotech PLC Earnings Release - Time Not SuppliedCCBN(Thu, Apr 25)
- Trinity Biotech Becomes Oversold (TRIB)at TheStreet(Wed, Apr 24)
- Trinity Biotech plc to Announce First Quarter Fiscal Year 2013 Financial ResultsGlobeNewswire(Tue, Apr 16)
- TRINITY BIOTECH PLC FinancialsEDGAR Online Financials(Wed, Apr 10)
- Are There Irish Stocks That Could Keep the St. Patrick’s Day Celebration Going?at Motley Fool(Mon, Mar 25)
- Steven Quay, CEO of Atossa Genetics, Inc. (ATOS), Interviews with The Wall Street TranscriptWall Street Transcript(Fri, Mar 15)
- Viacom Returns to TV Production and 4 Stocks Rocking 52-Week Highsat Wall St. Cheat Sheet(Wed, Mar 6)
- Trinity Biotech's CEO Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Mar 5)
- Trinity Biotech Announces Results for Fiscal Year 2012GlobeNewswire(Tue, Mar 5)
- Q4 2012 Trinity Biotech PLC Earnings Release - Time Not SuppliedCCBN(Tue, Mar 5)
- Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2012 Financial ResultsGlobeNewswire(Wed, Feb 20)
- BMRA: Initiating at OutperformZacks Small Cap Research(Wed, Jan 30)
- Trinity Biotech downgraded to Neutral from Buy at Roth Capitalat theflyonthewall.com(Tue, Jan 22)
Comparison
| Symbol | % Chg | Mkt Cap |
|---|
| TRIB | 0.00% | 365.13M |
| IDXX | 0.00% | 4.63B |
| NEOG | 0.00% | 1.32B |
| ABAX | 0.00% | 986.31M |
| VIVO | 0.00% | 906.05M |
Key Statistics
| Forward P/E (1 yr): | 17.22 |
|---|
| P/S (ttm): | 4.42 |
|---|
| Ex-Dividend Date: | 06-Jun-12 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.81 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.20 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 1.35 |
|---|
Business Summary
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market.
View More